3I was founded in 2013 to develop a cost-effective, accurate, and easy-to-use diagnostic that would improve the effectiveness of antibiotics-related clinical decisions.

Epigenomics is a molecular diagnostics company focused on developing innovative screening tests for cancer. Our lead product, Epi proColon, is the first and only FDA-approved blood-based test for colorectal cancer.  In the US today, 1 in 3, or 23 million eligible people, are not screened for colorectal cancer.  Epi proColon provides a convenient blood-based option to address this non-screened population.

Developing a universal Pneumococcal vaccine. SynAm Vaccine’s lead universal vaccine candidate addresses the critical unmet medical need in the marketplace by providing universal coverage against all 91 bacteria serotypes, while current marketed vaccines cover only a fraction of the serotypes.

In August of 2009 fNIR Devices, LLC started its operations after licensing various technologies from the estate of Dr. Britton Chance and the Drexel University.  fNIR Devices offerings, a line of Continuous Wave Functional Near Infrared imaging tools, are capable of monitoring brain’s hemodynamics and thereby the cognitive state of the subject in natural environments. fNIR technology employs specific wavelengths in an optical frequency window that can easily pass through a few centimeters for most tissues allowing monitoring of blood oxygenation changes. The relative changes of light intensity across time provide the researchers with information about neural activity.   Todate with over 250 brain imagers in the field, fNIR Devices is the premier supplier of fNIR Spectroscopy imaging systems for research and other non-clinical applications. 

Developing Innovations in Flow Cytometry

ExeGi leverages the growing advances in the field of the microbiome science to deliver novel, clinically supported, live biotherapeutic and probiotic treatments for a wide variety of unmet medical needs. We offer a high-potency probiotic medical food, Visbiome™, consisting of eight strains of live, freeze-dried lactic acid bacteria.  Visbiome is specially formulated for the dietary management of dysbiosis associated with IBS, ulcerative colitis, pouchitis, and hepatic encephalopathy. Visbiome is a non-drug therapy that addresses distinct nutritional requirements, to promote microbial balance, in people with IBS, ulcerative colitis, pouchitis, and hepatic encephalopathy that cannot be addressed by the modification of the diet alone. Visbiome is currently the subject of eight clinical trials, as a medical food, in several new disease states including HIV, autism spectrum disorders, and liver cirrhosis. Visbiome is intended to be used under the supervision of a physician.

Clinical stage company developing therapeutics for Dechenne Muscular Dystrophy.

US affiliate of EMS S/A of Brazil. Brace Pharma Capital is a strategic investment company formed by EMS S/A, the largest pharmaceutical company in Brazil, and high net worth biotech investors. We invest in innovative, life changing therapies for diseases with a high degree of unmet medical need and insufficient treatment options.